RNA (Atrium Therapeutics) Buyback Yield %: 0.00 (As of Jun. 27, 2026)


RNA Atrium Therapeutics Inc RNA
12 GF Score
Price $13.15
! 1 Warning Sign
View Full Analysis

What is Atrium Therapeutics Buyback Yield %?

Atrium Therapeutics RNA +3.21% 12 Buyback Yield % is 0.00 as of Jun. 27, 2026. GuruFocus rates RNA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 743 Biotechnology companies, Atrium Therapeutics ranks worse than 134589.37% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Atrium Therapeutics's current buyback yield was 0.00%.

Atrium Therapeutics Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Atrium Therapeutics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atrium Therapeutics Buyback Yield % Chart

Atrium Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Buyback Yield %
0.00 0.00 0.00

Atrium Therapeutics Quarterly Data
Dec23 Dec24 Mar25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

RNA vs RNAC, KROS, ARCT: Buyback Yield % Comparison

For the Biotechnology subindustry, Atrium Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atrium Therapeutics Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atrium Therapeutics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Atrium Therapeutics's Buyback Yield % falls into.


RNA
12GF Score
Atrium Therapeutics Inc RNA
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atrium Therapeutics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Atrium Therapeutics's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0) / 0
=N/A%

Atrium Therapeutics's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 0) / 228.70722
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of 0.00 mean?
Atrium Therapeutics (RNA) has a Buyback Yield % of 0.00 as of Jun. 27, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Atrium Therapeutics and its competitors. According to the industry distribution chart, Atrium Therapeutics ranks #999999 out of 743 companies in the Biotechnology industry.
Is Atrium Therapeutics' Buyback Yield % too high?
Atrium Therapeutics' current Buyback Yield % is 0.00. Based on the distribution chart, Atrium Therapeutics ranks #999999 out of 743 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Atrium Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Atrium Therapeutics' Buyback Yield % compare to RNAC and KROS?
According to the Biotechnology industry distribution chart, Atrium Therapeutics ranks #999999 out of 743 companies for Buyback Yield %. This places Atrium Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Atrium Therapeutics and its competitors. Atrium Therapeutics's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrium Therapeutics stock overvalued right now?
Atrium Therapeutics (RNA) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. Atrium Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Atrium Therapeutics (RNA), the current Buyback Yield % is 0.00 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atrium Therapeutics Business Description

Address 10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
12GF Score

Get the complete analysis for RNA

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.15
Price